|1.||Turull, A: 3 articles (08/2001 - 01/2000)|
|2.||Queralt, J: 3 articles (08/2001 - 01/2000)|
|3.||Piera, C: 1 article (04/2001)|
|1.||Membranous Glomerulonephritis (Membranous Nephropathy)
11/01/1999 - "This study investigated the role of COX-2 in the inflammatory processes of the kidneys of rats with passive Heymann nephritis (PHN), and focused of the effect of a selective COX-2 inhibitor, flosulide. "
11/01/1999 - "Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat."
10/01/1998 - "The effects of flosulide and aspirin were studied during the autologous phase of passive Heymann nephritis (PHN) in rats. "
10/01/1998 - "Different actions of the cyclooxygenase 2 selective inhibitor flosulide in rats with passive Heymann nephritis."
11/01/1999 - "Our results suggest that the therapeutic use of flosulide in proteinuria seems advantageous and deserves further studies because the basal prostaglandin levels remain unchanged in the low-dose-treated group, indicating that the compensatory capacity of prostaglandin production, which is essential for the regulation of renal hemodynamics, is maintained."
11/01/1999 - "Treatment with flosulide reduced the proteinuria to 26.1 +/- 9 mg/24 hr at 3 mg flosulide/kg body wt/day and 35.5 +/- 6 mg/24 hr at 9 mg/kg body wt/day, which was equivalent to a reduction of proteinuria by a maximum of 65% (P < 0.05). "
10/01/1998 - "Treatment with flosulide significantly reduced proteinuria as compared to aspirin treatment (64+/-15 vs. 109+/-14 mg/24 h, p < 0.05). "
02/01/1997 - "We assessed the gastrointestinal tolerability of flosulide (20 mg twice a day), a highly selective Cox-2 inhibitor with that of naproxen (500 mg twice a day), which has equal affinity for Cox-1 and -2 in 19 patients with osteoarthrosis in a randomized, double blind, crossover endoscopy study. "
12/01/1996 - "We assessed the gastroduodenal tolerability of flosulide (20 mg twice a day) in man and compared it with that of naproxen (500 mg twice a day) in a randomised, double blind crossover fashion in 19 patients with osteoarthrosis. "
08/01/2001 - "The anti-inflammatory treatment with flosulide (5 mg/kg x day), and indomethacin (1 mg/kg x day), reduced plantar edema by 98.0% and 74.4% respectively. "
01/01/2000 - "After 14 days of treatment, a clear dose-dependent inhibition of plantar edema was seen for both flosulide (ID50 lower than 0.1 mg/kg) and L-745,337 (ID50 = 0.4 mg/kg). "
08/01/1997 - "The doses that caused 50% inhibition in AA edema (ED50) were 2.4, 0.45 and 0.35 mg/ear for flosulide, L-745,337 and SC-57,666, respectively. "
12/08/1995 - "Although 20 and its oxygen linkage analog 2 (flosulide) are equipotent in the in vitro assays, compound 20 is more potent in the rat paw edema assay, has a longer t1/2 in squirrel monkeys, and seems less ulcergenic than 2 in rats."
04/01/2001 - "Acute anti-inflammatory doses of flosulide and indomethacin were determined on carrageenan paw edema and its effects on renal plasma flow (RPF) and glomerular filtration rate (GFR) were studied in normovolemic and hypovolemic rats. "
|2.||Aspirin (Acetylsalicylic Acid)
|3.||Cyclooxygenase 2 (Cyclooxygenase-2)
|9.||Interleukin-1 (Interleukin 1)
|10.||Non-Steroidal Anti-Inflammatory Agents (NSAIDs)